Heeding the advice of the Solicitor General, the US Supreme Court denied Gilead Sciences Inc.'s petition asking it to specify how False Claims Act cases should be resolved when the government knows about a company's alleged misrepresentations about a product but continues to pay for it.
In its Jan. 7 orders, the court denied three pharma-related petitions for certiorari. The other petitions were filed by





